Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, +35

New England Journal of Medicine

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

Chan-Young Ock, Bhumsuk Keam, Sehui Kim, +7

Clinical Cancer Research

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park, +226

The Lancet Oncology

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody

Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, +6

Cancer Immunology Immunotherapy

Week 6MedicineImmunologyBronchial NeoplasmImmune Checkpoint Inhibitor +6

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

Chan-Young Ock, Sehui Kim, Bhumsuk Keam, +12

Oncotarget

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors

Ryul Kim, Bhumsuk Keam, Sehui Kim, +10

BMC Cancer

Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma

Changhee Park, Kwon Joong Na, Hongyoon Choi, +14

Theranostics

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

Shin Hye Yoo, Bhumsuk Keam, Miso Kim, +6

ESMO Open

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer

Yu-Jung Kim, Bhumsuk Keam, Chan-Young Ock, +9

Lung Cancer

OncologyPathologyPhase Ii StudyImmune Checkpoint InhibitorCancer Treatment +3

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, +18

Cancer Discovery